drug

NVG-291

1 story · latest Sep 2, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by NervGen Pharma

Timeline

NervGen registers Phase 3 RESTORE trial of NVG-291 in chronic spinal cord injury

Sep 2Trial updateNervGen Pharma NVG-291

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.